April 11 - Swiss drugmaker Roche looks good vs its industry peers when it comes to free cash flow and margins, but StarMine shows Novartis and Sanofi’s 12 month forward earnings growth will outpace Roche’s.
Russia's looking up in the short time it said and done well last -- yeah is net margins for 2012 or more than doubled industries plus free cash but it is also looking good as. -- the industry by more than 16%. But if you want to hold a European -- stop till the end of the year. You want to look at -- is Novartis and Sanofi because star line. Showing that both of these stocks companies more signings growth and rocks in the next twelve months.